Zimmer Biomet Holdings, Inc.

Company facts

Industry

Orthopedic, Prosthetic & Surgical Appliances & Supplies

Headquarters

Warsaw, Indiana

Most recent report

8-K, filed Sep 8, 2026

Incorporated

Delaware

Filings on record

1,001+ filings

On EDGAR

CIK 1136869

Fiscal year ends

December

Filer status

Large accelerated filer

What to read: Jun 2026 10-Q

SECSift found 2 of 13 sections worth reading, with 1 positive, 3 notable, and 4 negative flags.

• Financial Statements (Item 1)

  Core financial statements for Q2 2026 with all results and key footnotes.
  Notable

  • Potential contingent consideration up to $720M and new $300M investment fund commitment.
  Negative

  • Global Foot & Ankle goodwill exceeds fair value by only 5% – a tight cushion even if expected.
  • Net litigation charges $22.8M in H1 2026, triple the $7.3M in H1 2025.

• Management's Discussion (Item 2)

  MD&A with real results, margins, buyback, debt, and litigation risks.
  Positive

  • Technology & Data, Bone Cement and Surgical net sales up 21.1% in Q2 2026, led by ROSA Robot and bone cement.
  Notable

  • $500.8M in stock repurchases in H1 2026 under a new $1.5B buyback program authorized February 2026.
  • Litigation liabilities estimated at $137.9M as of June 30, 2026; plus contingent consideration up to $720M and post-balance-sheet acquisitions for $245M initial cash.
  Negative

  • Outstanding debt of $7,479.0M; $1,201.5M current debt ($571.5M matures Dec 2026, $600M Feb 2027).
  • IRS proposed adjustments for 2013-2019; company disputes them but says future payments may be significant.

What changed: Jun 2026 vs. Mar 2026

About 5% of ZBH's Jun 2026 10-Q is new information. 13 paragraphs were added, 117 changed, and 21 removed. Below are the most important lines SECSift identified.

• Item 1 46
• Item 2 40
• Item 6 3
• Item 4 2
• Item 5 1